xPedite: A Study to Expedite DIPG and DMG Research

Inclusion Criteria:

1. Diagnosis of diffuse midline glioma according to the WHO 2021 Classification of Tumors of the Central Nervous System diagnostic criteria including diffuse intrinsic pontine glioma (DIPG). In the absence of a pathologically confirmed diagnosis, a grade IV glioma involving the thalamus, hypothalamus, brainstem, cerebellum, midbrain, or spinal cord, or with a pontine epicenter and diffuse involvement of the pons.
2. Patients with any performance status, comorbidity or disease severity are eligible
3. Patients or their legally-authorized representative must be willing and able to provide electronic, informed consent (and assent, if applicable)
4. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088).
5. Patients must be a resident of or receiving care within the United States or US territories.

Exclusion Criteria:

1. Patient or legally-authorized representative is unable to provide informed consent.
2. Patient or caregiver is unable to complete the PRO and ClinRO by an electronic platform.